Peter Thiel-Backed Psychedelic Firm Atai Sets Terms For US IPO, Sees $2.3B Valuation

Atai Life Sciences B.V., backed by billionaire investor Peter Thiel, has announced terms for its initial public offering.
See the SEC prospectus here.
The German company said it was looking to raise around $214.3 million through a U.S. IPO, targeting a valuation of about $2.3 billion.
The biotech startup, which explores the use of psychedelic treatments for mental health disorders, said it planned to sell around 14.29 million shares priced between $13 and $15 per share.
Launched in 2018, Atai has raised $362.3 million in cash so far.
Atai will be listed on the NASDAQ and will trade under the ticker symbol “ATAI.”
The company has built a pipeline of 10 development programs and six enabling technologies, each supported by its internal development and operational infrastructure.
One of its companies, Recognify Life Sciences, has initiated a Phase 2a trial in the U.S.
The company expects to initiate a Phase 2 trial for another program in 2021 and an additional three Phase 2 trials for other programs in 2022.
In April, the company filed to raise $100 million in an IPO.

Market News and Data brought to you by Benzinga APIs

The Benzinga Cannabis Capital Conference is coming to Florida

The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

The Benzinga Cannabis Capital Conference is coming to Florida